SCT650C not checked

Sinocelltech · Recombinant anti-IL-17A antibody

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
3 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Hidradenitis Suppurativa (HS)
Main trialPhase 2
“The purpose of this study is to assess efficacy, safety, pharmacokinetics and immunogenicity of subcutaneous SCT650C in patients with Moderate to Severe Hidradenitis Suppurativa”In the company’s words, NCT07244510 on ClinicalTrials.gov
Other names
Recombinant anti-IL-17A antibody

Other drugs for Hidradenitis Suppurativa (HS)

All 29 drugs for Hidradenitis Suppurativa (HS)

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 12 Mar 2027 Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa
Phase 2Unknown 1 Jul 2026 Efficacy and Safety of SCT650C in Participants With Axial Spondyloarthritis
Phase 1Unknown Nov 2023 Evaluate the Safety and Tolerability of SCT650C in Healthy Volunteers
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow SCT650C

Following is part of Solo: you see every change to SCT650C the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in